BIB vs. AMGN
BIB (ProShares Ultra Nasdaq Biotechnology) is Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%), while AMGN (Amgen Inc.) is a stock. Over the past 10 years, BIB returned 9.50%/yr vs 12.23%/yr for AMGN. A 0.65 correlation means they provide meaningful diversification when combined.
Performance
BIB vs. AMGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIB achieves a 10.33% return, which is significantly higher than AMGN's 6.85% return. Over the past 10 years, BIB has underperformed AMGN with an annualized return of 9.50%, while AMGN has yielded a comparatively higher 12.23% annualized return.
BIB
- 1D
- 3.51%
- 1M
- 7.37%
- YTD
- 10.33%
- 6M
- 5.76%
- 1Y
- 95.42%
- 3Y*
- 18.87%
- 5Y*
- -0.66%
- 10Y*
- 9.50%
AMGN
- 1D
- 2.11%
- 1M
- 1.60%
- YTD
- 6.85%
- 6M
- 5.53%
- 1Y
- 22.73%
- 3Y*
- 18.51%
- 5Y*
- 11.07%
- 10Y*
- 12.23%
BIB vs. AMGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 10.33% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
AMGN Amgen Inc. | 6.85% | 29.67% | -6.77% | 13.46% | 20.43% | 0.87% | -1.99% | 27.60% | 15.23% | 22.27% |
Correlation
The correlation between BIB and AMGN is 0.68, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.68 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.59 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.54 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.60 |
Correlation (All Time) Calculated using the full available price history since Apr 8, 2010 | 0.65 |
The correlation between BIB and AMGN shifts across timeframes, from 0.54 (5 years) to 0.68 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIB vs. AMGN — Risk / Return Rank
BIB
AMGN
BIB vs. AMGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Amgen Inc. (AMGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIB | AMGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.56 | ||
| Sortino ratioReturn per unit of downside risk | +1.57 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.17 | +0.18 |
| Calmar ratioReturn relative to maximum drawdown | 5.67 | 1.38 | +4.29 |
| Martin ratioReturn relative to average drawdown | 17.31 | 3.13 | +14.18 |
Loading charts...
Drawdowns
BIB vs. AMGN - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, which is greater than AMGN's maximum drawdown of -63.48%. Use the drawdown chart below to compare losses from any high point for BIB and AMGN.
Loading charts...
Drawdown Indicators
| BIB | AMGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -63.48% | -3.76% |
Max Drawdown (1Y)Largest decline over 1 year | -16.92% | -16.57% | -0.35% |
Max Drawdown (3Y)Largest decline over 3 years | -45.30% | -22.74% | -22.56% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -24.86% | -41.00% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -24.86% | -41.34% |
Current DrawdownCurrent decline from peak | -18.88% | -10.52% | -8.36% |
Average DrawdownAverage peak-to-trough decline | -32.71% | -16.77% | -15.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.53% | 7.30% | -1.77% |
Volatility
BIB vs. AMGN - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 13.51% compared to Amgen Inc. (AMGN) at 8.14%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than AMGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIB | AMGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.51% | 8.14% | +5.37% |
Volatility (6M)Calculated over the trailing 6-month period | 31.64% | 19.38% | +12.26% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.47% | 27.92% | +12.55% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.60% | 24.03% | +19.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.50% | 24.88% | +21.62% |
Dividends
BIB vs. AMGN - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.56%, less than AMGN's 2.84% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMGN Amgen Inc. | 2.84% | 2.91% | 3.45% | 2.96% | 2.95% | 3.13% | 2.78% | 2.41% | 2.71% | 2.65% | 2.74% | 1.95% |
BIB ProShares Ultra Nasdaq Biotechnology | 0.56% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
BIB and AMGN have a correlation of 0.68, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIB has higher volatility (13.51%) compared to AMGN (8.14%). In terms of maximum drawdown, BIB dropped -67.24% vs AMGN's -63.48%.
BIB currently has the higher Sharpe Ratio (2.38 vs 0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIB and AMGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer